Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Praxbind
Synonyms :
idarucizumab
Class :
Antidotes/Other
Brand Name :
Praxbind
Synonyms :
idarucizumab
Class :
Antidotes/Other
Dosage Forms & StrengthsÂ
Intravenous SolutionÂ
2.5gm/50ml vialÂ
Administered dose of 5 g through intravenous route with 2 separate vials containing 2.5 g/50 ml dose
Safety and efficacy are not seen in pediatricsÂ
Refer to the adult dosingÂ
may enhance the effect of anticoagulants
thrombolytic Agents may enhance the anticoagulant effect of anticoagulants
may enhance the adverse/toxic effect of anticoagulants
may enhance the adverse/toxic effect of anticoagulants
may enhance the adverse/toxic effect of anticoagulants
may enhance the adverse/toxic effect of anticoagulants
may enhance the adverse/toxic effect of anticoagulants
it may diminish the excretion rate when combined with permethrin, resulting in an enhanced serum level
it may increase the action of anticoagulant effect
it may increase the effect of anticoagulants
it may enhance the anticoagulant effect of anticoagulants
it may enhance the anticoagulant effect of anticoagulants
it may enhance the anticoagulant effect of anticoagulants
it may enhance the anticoagulant effect of anticoagulants
it may enhance the anticoagulant effect of anticoagulants
antiplatelet agents increase the effect of anticoagulants
antiplatelet agents increase the effect of anticoagulants
choline magnesium trisalicylate
salicylates may enhance the anticoagulant effect of anticoagulants
may enhance the adverse/toxic effect of anticoagulants
may enhance the adverse/toxic effect of anticoagulants
may enhance the adverse/toxic effect of anticoagulants
may increase the anticoagulant effect of anticoagulants
may increase the anticoagulant effect of anticoagulants
may increase the anticoagulant effect of anticoagulants
may increase the anticoagulant effect of anticoagulants
may increase the anticoagulant effect of anticoagulants
may increase the toxic effect of prostacyclin analogs
may enhance the anticoagulant effect of anticoagulants
may enhance the adverse/toxic effect of anticoagulants
may enhance the adverse/toxic effect of anticoagulants
may enhance the adverse/toxic effect of anticoagulants
may enhance the adverse/toxic effect of anticoagulants
may enhance the adverse/toxic effect of anticoagulants
may enhance the adverse/toxic effect of anticoagulants
may enhance the adverse/toxic effect of anticoagulants
may enhance the adverse/toxic effect of anticoagulants
may increase the anti-platelet effect of anti-coagulants agents
Actions and Spectrum:Â
idarucizumab is a monoclonal antibody fragment that works as a specific reversal agent for the anticoagulant dabigatran, a direct thrombin inhibitor used to prevent blood clot formation. Â
The action of idarucizumab binds with high affinity to dabigatran, thereby neutralizing its anticoagulant effects by forming an inactive complex that can be eliminated from the body. This rapid reversal effect can restore normal clotting parameters within minutes, making idarucizumab a valuable tool in emergencies where rapid reversal of dabigatran is needed, such as in cases of uncontrolled bleeding or emergency surgery. Â
The spectrum of idarucizumab is limited to reversing the anticoagulant effects of dabigatran only, and it does not affect other anticoagulants or coagulation factors. It is important to note that idarucizumab should only be used in emergencies and under the supervision of a healthcare professional, as its use can lead to an increased risk of thromboembolic events.Â
Frequency definedÂ
1-10%Â
DeliriumÂ
HypokalemiaÂ
PyrexiaÂ
ConstipationÂ
HeadacheÂ
PneumoniaÂ
Frequency not definedÂ
HypersensitivityÂ
Thromboembolic eventsÂ
Contraindication/Caution:Â
idarucizumab is generally considered safe and well-tolerated, but some contraindications and precautions should be considered when using this medication. These include:Â
Pregnancy consideration:Â Â
No adequate data are available regarding the usage of drugs during pregnancy. Â
Breastfeeding warnings:Â Â
It is yet to be discovered if the drug is excreted in breast milk. Hence use cautiously.Â
Pregnancy category:Â
Pharmacology:Â
idarucizumab is a monoclonal antibody fragment that binds with high affinity to the anticoagulant dabigatran, a direct thrombin inhibitor used to prevent blood clot formation. The binding of idarucizumab to dabigatran results in the formation of an inactive complex that can be eliminated from the body, thereby neutralizing its anticoagulant effects.Â
Pharmacodynamics:Â
The pharmacodynamics of idarucizumab involves its ability to bind to dabigatran and reverse its anticoagulant effects.Â
Dabigatran is a direct thrombin inhibitor that works by binding to and inhibiting thrombin, an enzyme necessary for blood clot formation. This anticoagulant effect is desired in patients with conditions such as or deep vein thrombosis atrial fibrillation, but it can also increase the risk of bleeding.Â
idarucizumab works as a specific reversal agent for dabigatran. By binding with high affinity to dabigatran, idarucizumab forms an inactive complex that can be eliminated from the body, thereby neutralizing the anticoagulant effects of dabigatran.Â
The reversal effect of idarucizumab is rapid, with normal clotting parameters restored minutes after administration. It is important to note that idarucizumab does not affect other anticoagulants or coagulation factors or interfere with measuring other laboratory parameters.Â
Pharmacokinetics:Â
DistributionÂ
The volume of distribution is 8.9LÂ
MetabolismÂ
The drug is metabolized through general protein synthesis.Â
It contributes to the metabolism of various antibodies.Â
Elimination and ExcretionÂ
The initial half-life is 47 minutes, and the terminal half-life is 10.3 hours.Â
The rate of total clearance is 47 mL/minÂ
The drug is excreted in 32.1% of urine
Administration:Â
idarucizumab is administered as an intravenous infusion over 5 to 10 minutes. The recommended dose is 5 grams (two 2.5-gram vials) of idarucizumab given as a single bolus injection. In emergencies, idarucizumab can be administered as a fixed dose without monitoring the patient’s coagulation status.Â
Before administration, the healthcare professional should confirm the patient’s identity and ensure the medication is administered to the correct patient. The vial of idarucizumab should be inspected visually for any discoloration, particulate matter, or leakage before use.Â
The medication should be administered intravenously and not mixed or co-administered with other medications. The infusion should be administered over 5 to 10 minutes, and the patient’s vital signs should be monitored during and after the infusion.Â
Patient information leafletÂ
Generic Name: idarucizumabÂ
Pronounced: EYE-da-roo-KIZ-ue-mabÂ
Why do we use idarucizumab?Â
idarucizumab reverses the anticoagulation of dabigatran, a direct thrombin inhibitor used to prevent blood clot formation.Â
idarucizumab is used in such emergencies to rapidly reverse the anticoagulant effects of dabigatran. By binding with high affinity to dabigatran, idarucizumab forms an inactive complex that can be eliminated from the body, thereby neutralizing the anticoagulant effects of dabigatran.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
